Skip to content
DataLookout
Menu

PLAQSIRISNCT06440317

Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 5 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date changed from estimate of Apr 2026 to Oct 22, 2026
    • Eligibility criteria expanded, about 4 words
    • Primary completion pushed from Apr 2027 to Oct 2027
    • Study completion pushed from May 2027 to Nov 2027
  2. Notable Primary completion date: Jan 2026 to Apr 2027
    • Start date: Jan 2025 to Apr 2026
    • Study completion date: Feb 2026 to May 2027
    v4
  3. Notable Start date: Jul 2024 to Jan 2025
    • Primary completion date: Jul 2025 to Jan 2026
    • Study completion date: Aug 2025 to Feb 2026
    v3
  4. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Primary completion date: Jun 2025 to Jul 2025
    • Study completion date: Jul 2025 to Aug 2025
    • Start date: Jun 2024 to Jul 2024
    • Site details revised
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Immunothrombosis : Concentration of platelet activation markers
Timeframe: 12 months after inclusion day

Secondary (2)

NETosis : Concentration of Neutrophil Extracellular Traps
Monocyte activation : Concentration of monocyte (CD14+)

Arms and interventions

Hemofiltration membranes (the oXiris® membrane and the HF1400 ® membrane)

Eligible patients for this study will undergo renal replacement therapy using two hemofiltration membranes commonly used in intensive care units.

Devices: Hemofiltration membranes (the oXiris membrane® and the HF1400® membrane)

Sites

1 site in 1 country

  • Hopital Haut-LévêquePessac, France